The legionella testing market is expected to register a CAGR of 9.1% during the forecast period. The market is experiencing considerable growth, due to factors, like the rising incidence of pneumonia and legionella-related illnesses and increasing demand for rapid advanced diagnostic techniques and technological advancements in the field of bacterial testing.
As per the Centers for Disease Control and Prevention (CDC) estimates, the United States witnessed 6,238 cases of Legionnaires disease in 2017. While this incidence number is relatively low, it is still an increment of 13.6% in the number of cases when compared to 2016 estimates. Legionnaires disease is not contagious, but the disease can be contracted by contaminated water droplets and mist. Similar to the United States, legionnaires disease in the EU countries is an uncommon and sporadic respiratory infection with low notification rates.
Despite the low overall number of cases of legionnaires disease incidence, the high growth rate of its prevalence globally is contributing to the growth of the legionella testing market. There has been a significant increase in the prevalence of the Legionnaires disease, globally, in the past five years. With the rising cases of legionella, there is a vital need for the management of disease, which helps in driving the overall market.
Key Market Trends
Urinary Antigen Test (UAT) Segment is Expected to Hold a Major Market Share in the Legionella Testing Market
Urinary Antigen Test (UAT) is a diagnostic tool, which provides rapid outcomes, with usually same-day results. Additionally, UAT is not resource-specific and technically intensive like culture-based tests. Since UAT does not require respiratory fluid samples, issues of sensitivity are also overcome.
According to the European Centre for Disease Prevention and Control (ECDC), in 2018, the largest number of deaths from Legionnaires disease was reported in France with 167 deaths confirmed. Moreover, in 2019, Belgium has reported an outbreak of legionellosis in the Evergem area in Flanders, Belgium. A cooling tower of a paper factory in the Evergem area is suspected as the source of infection. Currently, there is limited use of polymerase chain reaction (PCR)-based tests and other nucleic acid-based tests in the legionella market.
However, over the forecast period, this test category is expected to grow significantly, because it provides differential advantages, like detection of entire serogroups associated with legionella and rapid testing. Its widespread use in the current market is limited due to the high cost of PCR techniques.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same During the Forecast Period
North America has dominated the market studied, due to the increasing cases of patients suffering from legionella infections and the presence of key players in this region. Additionally, in order to manage the prevalence of LD, the Government of United States is increasing the awareness among the general public with the environmental legionella isolation techniques evaluation (ELITE) program, which may further augment the growth of the market.
In 2018, the ELITE Program planned to add additional performance evaluation criteria to its reports. This may allow regional, national, and international accrediting bodies to evaluate the laboratories in a variety of detection methods, including PCR and bacterial enzyme detection. According to the Centers for Disease Control and Prevention (CDC), estimated that nearly 10,000 cases of Legionnaires’ disease were reported in the United States in 2018. About one in 10 people will die who gets sick from Legionnaires disease. Thus, owing to above factors the market is expected to show growth over the forcast period in North America.
The legionella testing market is fragmented competitive and consists of several major players. The companies are implementing certain strategic initiatives, such as a merger, new product launch, acquisition, and partnerships, that help them in strengthening their market position. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Albagaia Ltd, Aquacert Ltd, Becton, Dickinson and Company, BioMerieux SA, Idexx Laboratories Inc., Merck Millipore (Merck KGaA), Pacific Water Technology, Pall Corporation (Danaher Corporation), Phigenics LLC, Qiagen NV and Thermo Fisher Scientific Inc.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support